[ET Net News Agency, 16 July 2021] CSPC Pharmaceutical Group Limited (01093) said
"SYSA1801", an antibody-drug conjugate developed by the group, has obtained approval of
its Investigational New Drug Application (IND) from the U.S. Food and Drug Administration
(FDA) to conduct clinical trials for advanced pancreatic cancer with positive Claudin 18.2
expression. The Phase I clinical trial will evaluate the safety, tolerability,
pharmacokinetics and preliminary efficacy of SYSA1801.
SYSA1801 is novel (first-in-class) anti-Claudin 18.2 monoclonal antibody-drug conjugate.
(RC)